BMRN:NASDAQ
Biomarin Pharmaceutical Inc
US$58,74
arrow_downward
-0,43%(-0,26) 1 HR
6 Jul, 12.53.08 GMT-4 · USD
search
Semua simbol
1 HR
5 HR
1BLN
6BLN
YTD
1THN
5THN
MAKS
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk BMRN...
Buka
US$58,72
Tinggi
US$58,78
Rendah
US$57,54
Kapitalisasi pasar
11,35 M
Volume rata-rata
2,33 jt
Volume
465,44 rb
Rasio P/E
42,86
Harga tinggi dalam 52 minggu terakhir
US$66,28
Harga rendah dalam 52 minggu terakhir
US$49,26
EPS
US$1,37
Beta
0,24
Saham beredar
193,28 jt
Jumlah karyawan
3 rb
Buka
US$58,72
Tinggi
US$58,78
Rendah
US$57,54
Kapitalisasi pasar
11,35 M
Volume rata-rata
2,33 jt
Volume
465,44 rb
Rasio P/E
42,86
Harga tinggi dalam 52 minggu terakhir
US$66,28
Harga rendah dalam 52 minggu terakhir
US$49,26
EPS
US$1,37
Beta
0,24
Saham beredar
193,28 jt
Jumlah karyawan
3 rb
Artikel berita
Dari berbagai sumber di seluruh web
Stock Traders Daily
·
11 jam yang lalu
Trading Systems Reacting to (BMRN) Volatility
ChartMill
·
2 hari yang lalu
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating
Profil
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Tentang Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Karyawan3,22 rb
DidirikanMar 1997
Kantor PusatSan Rafael, California, Amerika Serikat
Sektor-
Situsbiomarin.com
Konten AI mungkin berisi kesalahan. Pelajari lebih lanjut